Atrium Therapeutics Inc. Common Stock (RNA)

FairStock Score: 16/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I approach Atrium Therapeutics as a Graham-style bargain hunter, but this is not a business I can call safe. It is a clinical-stage biopharma pursuing RNA therapeutics for cardiomyopathies, with candidates ATR 1072 and ATR 1086. That is scientifically ambitious, but no durable moat is yet visible: no approved product, no demonstrated pricing power, and no multi-year record. The filed numbers are stark. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $3.0 million and net loss was $20.2 million, or $1.18 per diluted share. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $19.6 million and net loss was $16.6 million, or $0.97 per diluted share. The prior-year quarter ended 2025-06-30 had revenue of $3.8 million and a net loss of $12.9 million, or $0.75 per diluted share, so the latest loss widened. FairStock's calculations show a negative P/E of -1.42 at the $7.75 close on 2026-10-13, a P/B of 0.62, a Piotroski F-Score of 3/9, an Altman Z-Score of 1.95, and trailing free cash flow of -$56.5 million, a -42.6% FCF yield. The low debt-to-equity of 0.01 is a comfort, but negative cash flow of that size is the dominant fact. The market cap of $132.6 million is small relative to the losses. The FairStock Score of 16/100 and Lynch category of none—only 0 years of filed results—reinforce that this is speculative. The price may look low against book value, but without profits or stable revenue, I would demand a much wider margin of safety. Growth trajectory depends on pipeline events, not current earnings.

In plain English: Atrium Therapeutics is a biopharmaceutical company working on RNA medicines for heart diseases. It is not yet profitable: in the quarter ended 2026-06-30, it lost $20.2 million on $3.0 million of revenue. The stock trades near the low end of its 52-week range, but the business looks weak and the price is not clearly cheap given the losses and heavy cash use.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · fiscal Q1 2025 10-Q (period ended 2025-03-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer